^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

PARP INHIBITORS ARE EFFECTIVE IN NATURAL KILLER/T CELL LYMPHOMA VIA THE EXPRESSION OF LMO2

Published date:
05/11/2023
Excerpt:
Furthermore, fluzoparib, one of the PARPis, caused the accumulation of DNA damage, and LMO2 deficiency reduced the sensitivity of NKTCL cells to PARPis. Additionally, NKTCL patients with high LMO2 expression may have better progression-free survival and overall survival. Finally, the combination of fluzoparib and cisplatin exhibited significant synergistic effects both in vitro and in vivo.
Secondary therapy:
cisplatin